Thank you all visitors at ATS2024 in San Diego May 17-22!
We are proud that PExA was selected as Featured Company at the Respiratory Innovation Summit.
Check our invitation to the ATS2024, RIS2024 and to a Late Breaking Abstract from The Karolinska Institute describing miRNA detection in PEx-samples.
PExA
PExA develops and commercializes a unique technology aimed for the discovery of early biomarkers in the field of respiratory medicine.
We offer a non-invasive method for sampling of Respiratory Tract Lining Fluid (RTLF) originating from human’s most distal airways, providing new possibilities for the development of more accurate diagnostics and effective drugs.
![](https://pexa.se/wp-content/uploads/2015/10/doc.png)
How PExA works
The method is like a blood sample for lungs, however it is not invasive. Lung diseases often begin with pathological changes in the small airways, but there is currently no non-invasive, user-friendly technology to measure the status in these sections of the lungs.
Small droplets, or particles, that arise when small airways close and re-open, are collected from the exhaled air and sampled by impaction. The method open-ups for quantitative and reproducible measurements of changes in the composition of the lining fluid from small airways in respiratory disease.
Read More ››![](https://pexa.se/wp-content/uploads/2015/10/pexa_icon.png)
Product & Services
PExA provides a research instrument for lung research centres within the health services, in academia and in pharmaceutical companies, all of whom are currently actively looking for biomarkers.
Read more ››![](https://pexa.se/wp-content/uploads/2015/10/news.png)
Latest news
Get the latest news and press releases from PExA. Click on “read more” to access the news.
Read more ››